FDA approves higher dose of Novo Nordisk's Ozempic
The agency has cleared an additional, higher strength of injectable semaglutide, according to Managed Healthcare Executive.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 17 11:04 ETSource: Managed Healthcare Executive
The wire
- 01Managed Healthcare Executive reports the FDA has approved a higher dose of Ozempic, Novo Nordisk's injectable semaglutide.
- 02A new strength gives prescribers another titration step and changes what pharmacies must stock and what payers will be asked to cover.
- 03The specific dose, labeled indication and launch timing are not detailed in the report; prescribers should check the updated label.
From the source
Read at managedhealthcareexecutive.comFDA Approves Higher Dose of Ozempic